Oxycodone extended-release

DRUG3 trials

Sponsors

Ensysce Biosciences, Egalet Ltd

Conditions

HealthyModerate-to-severe Chronic Low Back PainModerate-to-severe Chronic Noncancer Pain

Phase 1

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

CompletedNCT02454712

Ensysce BiosciencesHealthy

Start: 2016-11-16End: 2018-01-18Updated: 2024-10-02

Phase 3

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

CompletedNCT02603705

Egalet LtdModerate-to-severe Chronic Noncancer Pain

Start: 2016-03-07End: 2017-06-15Updated: 2018-03-05

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

CompletedNCT02716857

Egalet LtdModerate-to-severe Chronic Low Back Pain

Start: 2016-03-31End: 2017-11-30Updated: 2018-03-05